Trastuzumab-refractory HER2-positive metastatic breast cancer - Use of tanespimycin, a novel Hsp90 inhibitor

American Journal of Hematology/ Oncology

Volumn 7, Issue 6, 2008, Pages

  Morris, Patrick ^a   Modi, Shanu ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CAPECITABINE; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; HEAT SHOCK PROTEIN 90; NAVELBINE; TAMOXIFEN; TANESPIMYCIN; TRASTUZUMAB;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER RESISTANCE; CASE REPORT; CELLULITIS; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MASTECTOMY; POSTOPERATIVE COMPLICATION;

EID: 73249114287     PISSN: 15429520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
2. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-2743.
3. Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem. 2006;6:1205-1214.
4. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther. 2002;2:3-24.
5. Basso AD, Solit DB, Munster PN, et al. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002;21:1159-1166.
6. Solit DB, Zheng FF, Drobnjak M, et al. 17-Allylamino-17- demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res. 2002;8:986-993.
7. Banerji U, Walton M, Raynaud F, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res. 2005;11:7023-7032.
8. Nowakowski GS, McCollum AK, Ames MM, et al. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006;12:6087-6093.
9. Ramanathan RK, Trump DL, Eiseman JL, et al. Phase I pharmacokinetic- pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin Cancer Res. 2005;11:3385-3391.
10. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005;23:1885-1893.
11. Solitolit DB, Ivy P, Kopil C, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res. 2007;13:1775-1782.
12. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol. 2005;23:1078-1087.
13. Solit DB, Basso AD, Olshen AB, et al. Inhibition of heat shock protein 90 function downregulates akt kinase and sensitizes tumors to taxol. Cancer Res. 2003;63:2139-2144.
14. Burger AM, Fiebig HH, Stinson SF, et al. 17-(allylamino)-17- demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs. 2004;15:377-387.
15. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol. 2007;25:5410-5417.
16. Dang CT, Dannenberg AJ, Subbaramaiah K, et al. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004;10:4062-4067.